Tirabrutinib

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

26 evidence topics · 24 sources

Generic, brand name and therapeutic class of product2 evidence topics · 5 sources
Dosage forms and strengths2 evidence topics · 2 sources
Average sales price and wholesale acquisition cost1 evidence topic · 1 source
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication1 evidence topic · 1 source
Pharmacology5 evidence topics · 5 sources
Contraindications/Warnings/Precautions/Adverse effects3 evidence topics · 3 sources
Special populations1 evidence topic · 1 source
Drug/Drug, drug/disease interactions3 evidence topics · 2 sources
Dosing and administration3 evidence topics · 3 sources
Access and distribution1 evidence topic · 1 source
Co-prescribed/Concomitant therapies1 evidence topic · 1 source
Product comparison2 evidence topics · 4 sources

Effect of Tirabrutinib on quality measures

No evidence found.